Pharmaceuticals company Neuland Laboratories announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Total Income for Q2FY25 at Rs 315.2 crore (-25.1% YoY). EBITDA for Q2FY25 at Rs 65.7 crore (-53.2% YoY). EBITDA Margin for Q2FY25 at 20.8% (decreased by 1260 bps YoY). PAT for Q2FY25 at Rs 32.0 crore (-64.1% YoY)*. Net Debt stood at Rs -94.3 crore as at Q2FY25 end compared to Rs -39.2 crore as at Q2FY24 end and Rs -110.2 crore as at Q1FY25 end. H1FY25 Financial Highlights: Total Income for H1FY25 at Rs 759.6 crore (-3.3% YoY). EBITDA for H1FY25 at Rs 194.3 crore (-18.9% YoY). EBITDA Margin for H1FY25 at 25.6% (decreased by 490 bps YoY). PAT for H1FY25 at Rs 130.3 crore (-13.9% YoY)*. Net Debt stood at Rs -94.3 crore as at H1FY25 end compared to Rs -39.2 crore as at H1FY24 end. Sucheth Davuluri: “The numbers of this quarter are subpar relative to how the business has been performing over the last few quarteRs However, they are in line with our commentary right at the beginning of the year as to how we see FY25 panning out. The inherent uneven nature of our business means that annual progression is a better indicator of the company’s prospects than quarterly performance. We continue to make progress on our strategic plans and are enthusiastic about sustainable long-term growth driven by customer acquisitions, deepening capabilities, agile capacity expansion and optimization of processes.” Saharsh Davuluri: “The revenues this quarter were driven by a few key molecules on the commercial CMS and GDS specialty side. Completion of additional manufacturing facilities in this year coupled with anticipated commercial launch of molecules on the CMS side gives us the confidence of achieving high growth in FY26 and beyond. We believe that the environment remains favourable for us in the medium to long term as indicated by customer interest and addition of early-stage projects.” Result PDF
Conference Call with Neuland Laboratories Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Neuland Laboratories announced Q1FY25 results: Total Income: Rs 444.4 crore, reflecting a YoY growth of 21.7% compared to Q1FY24 (Rs 365.0 crore) and a QoQ growth of 13.8% from Q4FY24 (Rs 390.4 crore). EBITDA: Rs 128.6 crore, representing a 29.5% increase from Q1FY24 (Rs 99.3 crore) and a 14.7% rise from Q4FY24 (Rs 112.2 crore). EBITDA Margin: 28.9%, an increase of 174 basis points from Q1FY24 (27.2%) and a slight increase of 21 basis points from Q4FY24 (28.7%). Exceptional Item: Rs 20.6 crore (noted for the quarter). Profit After Tax (PAT): Rs 98.3 crore, up 58.0% from Q1FY24 (Rs 62.2 crore) and a 45.5% increase from Q4FY24 (Rs 67.6 crore). PAT Margin: 22.1%, a growth of 510 basis points compared to Q1FY24 (17.0%) and up 480 basis points from Q4FY24 (17.3%). Earnings Per Share (EPS): Rs 76.6, reflecting a 58.0% increase from Q1FY24 (Rs 48.5) and a 45.5% rise from Q4FY24 (Rs 52.7). Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We recorded our highest ever quarterly revenues in Q1FY25 led by growth in the CMS business even as we recorded healthy EBITDA margins. We continue to maintain that FY25 will be a year of normalisation of revenue growth and subsequently margins as we continue to invest for growth. We expect our business to regain momentum from FY26 onwards basis our visibility from our portfolio of projects and products.” In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “The CMS revenues were driven by commercial molecules in line with our expectations as we outline our strategy over the years. As we evaluate our pipeline of projects and the flow of new projects, we remain enthusiastic on the strong potential of the CMS business over the long term. The GDS business continues to build on the strong base we have with quality focussed customers, even as our R&D; team is working on an exciting set of molecules to add to our portfolio.” Result PDF
Conference Call with Neuland Laboratories Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.